Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role in gastrointestinal homeostasis

Abstract

Background: The role of beta calcitonin gene-related peptide (beta-CGRP) in gastrointestinal tract is obscure, but experimental models suggest an effect on the homeostasis of the intestinal mucosa. We measured beta-CGRP circulating levels in a large series of subjects with a recent diagnosis of inflammatory bowel disease (IBD), in order to assess the potential role of this neuropeptide in IBD pathogenesis. Methods: Morning serum beta-CGRP levels were measured by ELISA (CUSABIO, China) in 96 patients recently diagnosed of IBD and compared with those belonging from 50 matched healthy controls (HC) and 50 chronic migraine (CM) patients. Results: Beta-CGRP levels were lower in patients with IBD (3.1±1.9 pg/mL; 2.9 [2.4-3.4] pg/mL) as compared to HC (4.7±2.6; 4.9 [4.0-5.8] pg/mL; p<0.001) and to CM patients (4.6±2.6; 4.7 [3.3-6.2] pg/mL; p<0.001). Beta-CGRP levels in CM were not significantly different to those of HC (p=0.92). Regarding IBD diagnostic subtypes, beta-CGRP levels for ulcerative colitis (3.0±1.9pg/mL; 2.5 [2.1-3.4] pg/mL) and Crohn's disease (3.3±2.0 pg/mL; 3.2 [2.4-3.9] pg/mL) were significantly lower to those of HC (p<0.01 and p<0.05, respectively) and CM (p<0.01 and p<0.05, respectively). Conclusions: We have found a significant reduction in serum beta-CGRP levels in patients with a recent diagnosis of all kinds of IBD as compared to two control groups without active intestinal disease, HC and CM, which may suggest a role for this neuropeptide in the pathophysiology of IBD. Our data indicate a protective role of beta-CGRP in the homeostasis of the alimentary tract.